Abstract. It was previously reported that adenosine-2A (A 2A ) receptors interact with dopamine-2 (D 2 ) receptors on a molecular level. The aim of the current study was to investigate the functional output of this interaction. In vivo microdialysis was used to assess the effects of an antagonist of A 2A receptors, ZM 241385, and an antagonist of D 2 receptors haloperidol, either alone or in combination, on brain catecholamine levels. It was found that ZM 241385 did not alter catecholamine levels by its own, but potentiated haloperidol-induced dopamine and norepinephrine release in the nucleus accumbens and prefrontal cortex, respectively. In vivo electrophysiology was used to assess the effect of an agonist (CGS 216820) and an antagonist (ZM 241385) of A 2A receptors on the excitability of dopamine and norepinephrine neurons. It was found that CGS 216820 dose-dependently inhibited dopamine and norepinephrine neurons and ZM 241385 reversed this inhibition. In conclusion, those A 2A receptors modulate brain catecholamine transmission, and this modulation is mediated, at least in part, via the regulation of excitability of norepinephrine and dopamine neurons. The ability of antagonists of A 2A receptors to potentiate the effect of haloperidol on brain norepinephrine and dopamine levels may enhance its clinical efficacy as an antipsychotic drug.
Introduction
Adenosine, or (2R, 3R, 4S, 5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl) oxolane-3, 4-diol, is a nucleoside composed of a purine nucleotide adenine and ribose. Adenosine plays an important role in multiple biological processes. As a part of adenosine triphosphate (ATP), it mediates bioenergetical processes in biological cells. In neurons, ATP supplies the energy for the storage of molecules of neurotransmitters to the synaptic vesicles by vesicular neurotransmitter transporters (Takeda and Ueda 2017) . During this process, ATP is metabolized to adenosine and its mono (AMP)-and diphosphates (ADP). These products of ATP hydrolysis are also stored in the synaptic vesicles (Cunha et al. 1996a) .
Adenosine is not only co-released with other neurotransmitters as a side product of ATP hydrolysis, but also plays an important role in neuronal transmission (Cunha et al. 1996b) . There are four known subtypes of adenosine receptors: the Gα I -protein-coupled A 1 and A 3 receptors and Gα S -coupled A 2A and A 2B receptors (Krügel 2016) . The A 2A and A 2B receptors are expressed on different types of brain neurons and glial cells. The A 2B receptors are widely distributed across the brain, while A 2A are almost exclusively expressed in the striatum, hippocampus, and prefrontal cortex (PFC) (Sebastiao and Ribeiro 1996) . The A 2A receptors play an important role in the regulation of neuronal activity in the limbic areas of the brain. It was reported that agonists of A 2A receptors stimulate glutamate and acetylcholine release, depolarize neurons in hippocampus and striatum, and inhibit GABA release in the PFC (Cunha et al. 1996c) .
It was shown that A 2A receptors interact with dopamine (DA) D 2 receptors (Ferre et al. 1991a (Ferre et al. , 1991b . The Gα Scoupled A 2A receptors form a dimmer with Gα I -coupled D 2 receptors. The A 2A -D 2 dimmer couples to Gα Q/Z -protein and activates calcium-rather than cAMP-dependent signal transduction pathways. It has been suggested that A 2A -D 2 interaction plays an important role in the excitatory effect of A 2A receptor on the neuronal circuits (Fuxe et al. 2014 ). Since DA system in general and D 2 receptors in particular are essential in schizophrenia and Parkinson disease, it is possible that A 2A receptors are also involved in pathophysiology and treatment of these disorders. Indeed, it was reported that an antagonist of A 2A receptors, ZM 241385, potentiates the stimulatory effect of L-DOPA, a dopamine precursor and a first-choice drug for the treatment of Parkinson disease, on extracellular DA levels in the rat striatum (Golembiowska and Dziubina 2004 , 2012a , 2012b . Other studies reported a potent anti-cataleptic effect of ZM 241385 and other antagonist of A 2A receptors (Kanda et al. 1994; Shiozaki et al. 1999; Varty et al. 2008; Trevitt et al. 2009; Collins et al. 2012; Atack et al. 2014) . However, the exact mechanism of A 2A receptor-mediated modulation of brain DA transmission was not yet investigated.
It was also reported that dipyridamole, an adenosine reuptake inhibitor, potentiates the effect of haloperidol, an antagonist of D 2 receptors and an antipsychotic drug, on the negative and cognitive symptoms of schizophrenia (Akhondzadeh et al. 2000) . Knockout mice lacking A 2A receptors demonstrated cognitive and behavioral impairments which resembled the negative symptoms of schizophrenia (Moscoso-Castro et al. 2016) . Because of the role of limbic norepinephrine (NE) in the negative and cognitive symptoms of schizophrenia (Yamamoto and Hornykiewicz 2004) , it is possible that A 2A receptors modulate NE transmission. Although the modulatory effect of A 2 receptors on NE transmission was previously observed in the spinal cord Proudfit 1990a, 1990b) , their effect on limbic NE pathways was not yet investigated.
The present study aimed to investigate the neurophysiological mechanism of the modulatory effect of A 2A receptors on limbic DA and NE neurotransmission. Using in vivo microdialysis, the effects of an antagonist of A 2A receptors, ZM 241385, and an antagonist of D 2 receptors, haloperidol, and their combination, on DA and NE release in the nucleus accumbens (NAcc) and prefrontal cortex (PFC) was examined. Using in vivo electrophysiology, the effects of an agonist of A 2A receptors, CGS 216820, and their antagonist ZM 241385 on the excitability of DA neurons of the ventral tegmental area (VTA) and NE neurons of the locus coeruleus (LC) were investigated.
Materials and Methods

Animals
Male Wistar rats (300-350 g; Harlan, Horst, the Netherlands) were used for the experiments. The animals were housed in plastic cages (30 × 30 × 40 cm) and had access to food and water ad libitum. Experiments were conducted in accordance with the Directive 2010/63/EU of the European Parliament and of the Council of the European Union and were approved by the Animal Care Committee of the University of Groningen.
Surgery
Rats were anesthetized with isoflurane (2%, 800 ml/min O 2 ). Bupivacaine/adrenaline solution was used for local analgesia. The animals were placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA). 3 mm hole was drilled in the skull to allow insertion of microdialysis probe or electrode (for PFC: 3.4 mm anterior to bregma and 0.8 mm lateral to midline; for NAcc: 2.0 mm anterior to bregma and 1.2 mm lateral to midline; for LC: 8.2 mm posterior to bregma and 1.2 mm lateral to midline; for VTA: 5.0 posterior to bregma and 0.7 lateral to midline) (Paxinos and Watson 2014) .
Microdialysis
Microdialysis experiments were performed as previously described (Dremencov et al. 2004a (Dremencov et al. , 2005 Westerink and Cremers 2007; Allers et al. 2010; Cremers et al. 2010; Bloms-Funke et al. 2011; Flik et al. 2011 Flik et al. , 2015 Yamada et al. 2013; Visser et al. 2015) . I-shaped probes (Hospal AN 69 membrane, Brainlink, Groningen, the Netherlands) were inserted in the PFC (5.0 mm dorsal from the brain surface, 4 mm exposed surface probe) or NAcc (7.9 mm dorsal from the brain surface, 1.5 mm exposed surface probe); experiments were carried out 24-48 hours after surgery. The microdialysis probes were connected with flexible polyether ether ketone (PEEK) tubes to microperfusion pumps (CMA 102). The dialysis probes were perfused with a Ringer buffer containing 147 mM NaCl, 3.0 mM KCl, 1.2 mM CaCl 2 , and 1.2 mM MgCl 2 , at a flow rate of 1.5 μl/min. Microdialysis samples were collected every 20 minutes. After completion of the experiments rats were sacrificed and brains were removed and stored for three days in paraformaldehyde solution (4% m/v). The position of each probe was verified histologically according to Paxinos and Watson (2014) , by making coronal sections of the brain.
Analysis of monoamines levels in dialysates
Neurotransmitters were separated using high-performance liquid chromatography (HPLC). Their concentrations were determined using tandem mass spectrometric detection and quantified by area under the peak integration method. Two microliters of an internal standard containing 100 nM of NE and DA were added to original 20 μl-samples. The resulting 22 μl mixes were derivatized for 1 minute with 40 μl of the derivatization reagent containing 8 mg of SymDAQ dissolved in 5 ml of 0.5 M NaHCO 3 , 4.5 ml of ultrapure water, 0.5 ml of methanol, and 20 ml of 2-mercaptoethanol. After derivatization, 40 μl of each sample were injected by an automatic sampler device (Sil-10 ADvp auto-sampler, Shimadzu, Tokyo, Japan). Chromatographic separation was performed on a reversed-phase column (150 × 2.0 mm Synergi MAX-RP, 4 mm, Phenomenex, Torrance, CA, USA). Samples were eluted using a linear gradient of 5-70% of acetonitrile with 0.1% formic in ultrapure water with 0.1% formic acid for 6 minutes at a flow rate of 0.3 ml/minute. The flow was mixed (postcolumn) with a makeup flow of 0.15 ml/minute of the mobile phase (acetonitrile with 0.1% formic acid in ultrapure water with 0.1% formic acid), and directed to mass spectrometer (API 4000, Applied Biosystems, Foster City, CA, USA). Mass spectra were determined in multi-reaction mode (MRM) for 3-7 minutes (Dremencov et al. 2004a (Dremencov et al. , 2005 Westerink and Cremers 2007; Allers et al. 2010; Cremers et al. 2010; Bloms-Funke et al. 2011; Flik et al. 2011 Flik et al. , 2015 Yamada et al. 2013; Visser et al. 2015) .
Electrophysiology
Extracellular single-unit in vivo electrophysiological recordings were performed, as previously described (Dremencov et al. 2007a (Dremencov et al. , 2007b (Dremencov et al. , 2009 (Dremencov et al. , 2017 Flik et al. 2011) . Surgical anesthesia was maintained using propofol (20%) continuously administered intravenously (i.v., via a catheter placed in the lateral tail vein) at a rate 20 µl/min (for 300 g rat) by a microperfusion pump (CMA 102, Stockholm, Sweden). The body temperature was maintained between 36°C and 37°C using a heating pad (Gaymor Instruments, Orchard Park, NY, USA). Glass-pipettes (TW100F-3, WPI; FL, USA) were pulled to a fine tip with a diameter of ~1 μm with a programmable puller (Sutter, Novato, CA, USA) and filled with a 2 M sodium chloride (NaCl) solution. The impedances of electrodes ranged between 8 and 10 MΩ. The pipettes were lowered into the LC or VTA using a hydraulic micropositioner (David Kopf Instruments, Tujunga, CA). Signals were amplified using an 1800 Microelectrode AC amplifier (A-M systems, Inc.; WA, USA). The signal was subsequently fed into a Micro 1401 ADC interface unit and recorded on a computer using the Spike-2 software package (CED; Cambridge, UK). The NE and DA neurons were identified by: (1) their location (NE neurons of the LC: 8.0-8.3 mm posterior to bregma, 1.2-1.4 mm lateral to the midline, and 5.5-7.5 mm ventral to the brain surface; DA neurons of the VTA: 4.5-5.5 mm posterior to bregma, 0.6-0.8 mm lateral to the midline, and 7.0-8.5 mm ventral to the brain surface); (2) firing pattern (NE neurons: regular firing rate of 0.5-5.0 Hz, positive action potential of long duration of 0.8-1.2 ms and a characteristic burst discharge in response to nociceptive pinch of the contralateral hind paw; DA neurons: slow irregular firing-rate of 0.5-10 Hz, mixed single spike and burst firing, tri-phasic action potentials with a dominant positive component, a minor one with duration over 2.5 ms and a "notch" often present on the initial rising phase and a minimum 1.1 ms duration from action potential initiation to the negative trough); (3) their response to the specific antagonist (NE neurons: α 2 -adrenergic receptor agonist clonidine; DA neurons: D 2 receptor agonist apomorphine).
Drugs
CGS 216820, ZM 241385, apomorphine, and clonidine were purchased from Tocris Biosciences. CGS 216820 and ZM 241385 were dissolved in 10% solution of dimethyl sulfoxide (DMSO) in distilled water at the concentrations 0.5 and 1.0 mg/ml, respectively. Apomorphine and clonidine were dissolved in distilled water at the concentrations 0.02 and 0.02 mg/ml, respectively. Haloperidol was dissolved in 10% tartaric acid at pH = 1 and then in distilled water at the concentration 0.25 mg/ml; the pH of the final solution was close to seven.
Animal handling
The animals for in vivo microdialysis experiments were randomly divided into four groups: (1) vehicle+vehicle, (2) ZM 241385+vehicle, (3) vehicle+haloperidol, and (4) ZM 241385+haloperidol. The first group was administered 2.0 ml/kg 10% DMSO in distilled water (intraperitoneally (i.p.) ; 40 min after the beginning of the experiment) and 2.0 ml/kg of distilled water (i.p.; 60 min after DMSO administration). The second group was administered 1.0 mg/kg of ZM 2431385 (i.p.; 40 min after the beginning of the experiment) and 2.0 ml/kg of distilled water (i.p.; 60 min after ZM 241385 administration). The third group was administered 2.0 ml/kg of 10% DMSO in distilled water (i.p.; 40 min after the beginning of the experiment) and 0.50 mg/kg of haloperidol (i.p.; 60 min after DMSO administration). The fourth group was administered 1.0 mg/kg of ZM 2431385 (i.p.; 40 min after the beginning of the experiment) and 0.5 mg/kg of haloperidol (i.p.; 60 min after ZM 241385 administration).
The animals participating in in vivo electrophysiology experiments were randomly divided into two groups. The first group was used to assess the effect of consecutive administration of vehicle, CGS 216820, ZM 241385, and apomorphine on the excitability of DA neurons in the VTA. The second group was used to assess the effect of consecutive administration of vehicle, CGS 216820, ZM 241385, and clonidine on the excitability of NE neurons in the LC. During the electrophysiology experiments, when a DA or NE neuron was identified and recorded for at least 100 s, vehicle (10% DMSO in distilled water; 1 ml/kg), was administered intravenously (i.v.; via catheter placed in the lateral tail vein). Afterward, CGS 216820 was administered at cumulative doses of 0.05, 0.15, and 0.50 mg/kg (at least 100, 200, and 300 s after vehicle administration), respectively, and after the firing activity of the neuron, was stabilized from the previous injection. Following CGS 216820, ZM 241385 was administered at cumulative doses of 0.10, 0.30, and 1.00 mg/kg (at least 100, 200, and 300 s after last CGS 216820 administration, respectively, and after the firing activity of the neuron, was stabilized from the previous injection). One hundred minutes after the last ZM 241385 injection, apomorphine (0.02 mg/kg; for DA neurons) or clonidine (0.02 mg/kg; for NE neurons) were administered.
Statistical analyses
For electrophysiology experiments, the mean firing rate recorded during 100 consecutive seconds, after the stabilization of firing activity, was considered as a baseline; for microdialysis experiments, mean DA or NE concentration in four consecutive fractions, with variability less than 50%, was taken as baseline. All data are expressed as mean ± SEM % of baseline. One-way analysis of variance (ANOVA) for repeated measurements, followed by Bonferroni post-hoc test, was used for electrophysiology experiments. Two-way (time, versus treatment group) ANOVA for repeated measurements, followed by Bonferroni post-hoc test, was used for microdialysis experiments. The level of significance was set as p < 0.05.
Results
Basal levels of catecholamines and basal firing activity of catecholamine-secreting neurons
The basal DA levels were 1.29 ± 0.34 nM in the NAcc and 0.15 ± 0.03 nM in the PFC. The basal NE levels were 2.95 ± 0.78 nM in the NAcc and 1.42 ± 0.48 nM in the PFC. The basal firing rates of DA neurons of the VTA and NE neurons of the LC were 6.28 ± 1.45 and 2.90 ± 1.23 Hz, respectively.
ZM 241385 potentiated haloperidol-induced increase in extracellular DA levels in the NAcc, but not in the PFC
ZM 241385, administered alone, did not alter extracellular DA levels in the NAcc or in the PFC. Haloperidol administration resulted in a 200%-increase in DA levels in the NAcc. Co-administration of ZM 241385 and halo- Figure 1 . Effects of ZM 241385, haloperidol, and their combination on extracellular dopamine (DA) levels in the rat nucleus accumbens (NAcc; A) and prefrontal cortex (PFC; B). The first arrow marks the administration of ZM 241385 (1.0 mg/kg, i.p.) or its vehicle (10% DMSO in distilled water, 2.0 ml/kg, i.p.). The second arrow marks the administration of haloperidol (0.5 mg/kg, i.p.) or its vehicle (2.0 ml/ kg distilled water, i.p.). * p < 0.05 vs. baseline, haloperidol-administered rats; # p < 0.05 vs. baseline, ZM 241385+haloperidol-administered rats; ~ p < 0.05 vs. vehicle, haloperidol-administered rats; + p < 0.05 vs. vehicle, ZM 241385+haloperidol-administered rats; ^ p < 0.05 vs. haloperidol, ZM 241385+haloperidol-administered rats; Bonferoni post-hoc test.
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peridol resulted in a 500%-increase in extracellular DA levels in the NAcc, which was higher than the 200%-increase in extracellular DA levels produced by haloperidol administered alone (Fig. 1A) . Similar 200%-increase in cortical DA levels was observed in rats administered with haloperidol alone or with ZM 241385 and haloperidol (Fig. 1B) . The details of statistical analysis are provided in the Table 1 . 
ZM 241385 potentiated haloperidol-induced increase in extracellular NE levels in the PFC, but not in the NAcc
ZM 241385, haloperidol, or their combination did not significantly alter extracellular NE levels in the NAcc (Fig. 2A) . ZM 241385, administered alone, did not alter cortical NE levels as well. Haloperidol, administered by its own, slightly increased NE levels in the PFC (150% of baseline). However, co-administration of ZM 241385 and haloperidol produced significantly greater 200%-increase in extracellular NE levels in the PFC (Fig. 2B) . The numbers of the animals and details of statistical analysis are provided in the Table 1 .
CGS 21680 inhibited DA neuronal firing activity in the VTA, and ZM 241385 reversed this inhibition
The i.v. administration of CGS 21680 significantly and dose-dependently inhibited the firing activity of DA neurons. Subsequent administration of ZM 241385 partially reversed CGS 21680-induced inhibition of DA neurons, in a dose-dependent manner. The subsequent administration of apomorphine inhibited DA neurons in the VTA again (Fig. 3) . The details of statistical analysis are provided in the Table 1 .
CGS 21680 inhibited NE neuronal firing activity in the LC, and ZM 241385 reversed this inhibition
The i.v. administration of CGS 21680 significantly and dose-dependently inhibited the firing activity of NE neurons. Subsequent administration of ZM 241385 partially reversed CGS 21680-induced inhibition of NE neurons, in a dose-dependent manner. The subsequent administration of clonidine inhibited NE neurons in the LC again (Fig. 4) . The numbers of the animals and details of statistical analysis are provided in the Table 1 .
Discussion
The results of the current study demonstrated that selective antagonist of A 2A receptors, ZM 241385, administered alone, did not alter extracellular levels of NE or DA in the NAcc or in the PFC. However, ZM 241385 potentiated haloperidol-induced increase in DA levels in the NAcc and NE levels in the PFC. Selective agonist of A 2A receptors, CGS 21680, dose-dependently inhibited the firing activity of DA neurons of the VTA and NE neurons of the LC. The CGS 21680-induced inhibition of DA and NE neurons was partially reversed by ZM 241385. DA and NE neurons were inhibited after the subsequent administration of apomorphine and clonidine, respectively. Our finding that an acute administration of haloperidol increased extracellular levels of DA in the NAcc and PFC, and of NE in the PFC, is in line with previous studies (Prus et al. 2007; Madularu et al. 2014; Tanda et al. 2015) . The accumbal levels of NE were not affected by haloperidol, as previously reported (Zhang et al. 2000) .
An acute systemic administration of the selective antagonist of A 2A receptors, ZM 241385, did not alter extracellular levels of DA in the NAcc and PFC. Similarly, Gołembiowska and Dziubina (2004) reported that intra-striatal administra- 
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tion of ZM 241385 did not alter local DA levels. Chronic systemic administration of ZM 241385 or of another antagonist of A 2A receptors, CSC, did not alter striatal DA levels as well (Golembiowska and Dziubina 2012a) . The novel antagonist of A 2A and A 1 receptors, JNJ-40255293, did not alter cortical and striatal DA levels as well (Atack et al. 2014) . Interestingly, CSC increased striatal DA levels in rats pre-treated with the VMAT inhibitor reserpine, while ZM 241385 had no effect Dziubina 2012a, 2012b) . However, it was reported that another antagonist of A 2A receptors, KW6002, induced a robust increase in DA release in the NAcc (Harper et al. 2006 Carter (1997) reported that neither the agonist of A 2 receptors, CGS 21680, nor the A 1/2 antagonist caffeine, alter NE release in the rat hippocampus.
It was observed that the selective antagonist of A 2A receptors, ZM 241385, potentiates haloperidol-induced increase in DA levels in the NAcc. Interestingly, ZM 241385 and CSC also potentiated L-DOPA-induced DA in the striatum of intact, but not DA-denervated rats. The potentiating effect of ZM 241385 and CSC on striatal DA release was also observed in reserpine-pretreated rats (Golembiowska and Dziubina 2004 , 2012a , 2012b . It is possible that the mechanisms of A 2A -mediated potentiation haloperidol-and L-DOPAinduced DA release are complimentary. Both haloperidol and L-DOPA are increasing DA bioavailability: haloperidol by blocking of D 2 receptors and subsequent activation of DA neurons, and L-DOPA by an increase in the synthesis of DA in the neurons. It is possible that antagonists of A 2A receptors diminish the inhibitory effect of DA and/or potentiate the stimulatory effect of haloperidol on the excitability of DA neurons, via a mechanism involving dimerization of A 2A and D 2 receptors (Fig. 5) .
The results of this study demonstrated that ZM 241385 potentiated the haloperidol-induced NE release in the PFC. It was previously reported that A 2 receptors regulate NE neurotransmission in the spinal cord and this regulation play a role in the pain modulation (Aran and Proudfit 1990a) . It was also suggested that A 2 receptors interact with α 1 -and α 2 -adreneric ones (Aran and Proudfit 1990b) . It has been shown that cortical α 1 -adrenoceptors have a stimulatory (Stone et al. 2007) , and α 2 -adrenoceptors -an inhibitory effect on central NE neurotransmission (Shirokawa et al. 2003) . Haloperidol is a potent D 2 receptor antagonist with a minor affinity for α 1 - (Richelson and Souder 2000) and α 2 -adrenoceptors (Richelson and Nelson 1984) . It is possible that ZM 241385, via a mechanism involving dimerization of A 2 and α 1 -and/ or α 2 -adrenocpetors, diminishes the α 1 -mediated inhibitory effect of haloperidol on NE transmission. Alternatively, haloperidol may stimulate the α 2 -adrenocpetor-mediated stimulatory effect of haloperidol in NE tone (Fig. 5) . However, further studies should be performed to investigate molecular and functional interactions between adenosine and NE receptors in the brain. Based on our finding and previous reports, it can be summarized that A 2A receptors modulate NE and DA transmission in the brain. We performed in vivo electrophysiological experiments to examine whether this modulation involves an alteration of the firing activity of NE and DA neurons. We have wound that the selective agonist of A 2A receptors, CGS 21680, dose-dependently inhibited the firing activity of NE neurons in the LC and DA neurons in the VTA and these inhibitions were reversed by ZM 241385, also in a dose-dependent mater. To our best knowledge, it was a first direct examination of the effect of A 2A ligands of the excitability of catecholamine-secreting neurons in in vivo conditions. It was, however, previously reported that CGS21680 facilitated the excitatory post-synaptic potentials (EPSPs) in hippocampal slices (Rebola et al. 2003) and potentiated metabotropic glutamate receptor-5 (mGlu 5 )-induced EPSPs is corticostriatal slices (Domenici et al. 2004 ). On the other hand, D 2 -and mGlu 5 -induced EPSP is corticostriatal slices were diminished by ZM 241385 (Tozzi et al. 2011) . Since striatal neurons negatively regulate DA neuronal firing activity in the VTA (Dremencov et al. 2006) , it is possible that the ability of CGS 21680 and ZM 241385 to modulate the excitability of DA neurons in the VTA is mediated, at least in part, via the activation and blocking of A 2A receptors in the striatum. Since A 2A receptors modulate the cortical NE release via a mechanism potentially involving interaction between A 2A and α 1 -and/or α 2 -adrenoceptors, it is possible that CGS 21680 and ZM 241385 modulate the excitability of NE neurons in the LC via an activation and inhibition of A 2A receptors located in the cortex.
In conclusion, those A 2A antagonists potentiate haloperidol-induced DA and NE release in the NAcc and PFC, respectively. This potentiation is mediated, at least in part, via the alteration of firing activity of NE and DA neurons in the LC and VTA, respectively. The ability of A 2A antagonists to potentiate striatal DA release may diminish some negative side effects of antipsychotic drugs, such as catalepsy. Indeed, several antagonists of A 2A receptors, such as KF1783, KW-6002, SCH 412348, SCH 58261, Lu-AA47070 and JNJ-40255293 reduced haloperidol-induced catalepsy in rats (Kanda et al. 1994; Shiozaki et al. 1999; Varty et al. 2008; Trevitt et al. 2009; Collins et al. 2012; Atack et al. 2014 ). Since cortical NE play an important role in memory and cognition, the ability of A 2A antagonists to potentiate NE transmission can improve the clinical efficacy of antipsychotic drugs, and especially in the treatment of negative and cognitive symptoms of schizophrenia (Yamamoto and Hornykiewicz 2004) . Figure 5 . Interaction between adenosine, dopamine, and norepinephrine systems. PFC, prefrontal cortex; NAcc, nucleus accumbens; VTA, ventral tegmental area; A 2A , adenosine-2A receptors; D 2 , dopamine-2 receptors; α 1/2 , alpha-1/2 adrenoceptors; "+" or solid line, excitatory pathway; "-" or dotted line, inhibitory pathway.
